Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 15;8(7):e128.
doi: 10.1002/hem3.128. eCollection 2024 Jul.

CD49d expression is included in a revised 4-factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real-world experience

Riccardo Bomben  1 , Antonella Zucchetto  1 , Roberta Laureana  2 , Annalisa Chiarenza  3 , Jacopo Olivieri  4 , Erika Tissino  1 , Francesca M Rossi  1 , Filippo Vit  1 , Tamara Bittolo  1 , Robel Papotti  1 , Federico Pozzo  1 , Annalisa Gaglio  1 , Massimo Degan  1 , Jerry Polesel  5 , Roberto Marasca  6   7 , Andrea Visentin  8 , Riccardo Moia  9 , Idanna Innocenti  10 , Candida Vitale  11 , Roberta Murru  12 , Marzia Varettoni  13 , Agostino Tafuri  14 , Francesco Zaja  15 , Massimiliano Postorino  2 , Enrica A Martino  16 , Adalgisa Condoluci  17 , Davide Rossi  17 , Antonio Cuneo  18 , Francesco Di Raimondo  3 , Paolo Sportoletti  19 , Ilaria Del Giudice  20 , Robin Foà  20 , Francesca R Mauro  20 , Marta Coscia  11 , Luca Laurenti  10 , Gianluca Gaidano  9 , Livio Trentin  8 , Maria I Del Principe  2 , Massimo Gentile  16   21 , Valter Gattei  1
Affiliations

CD49d expression is included in a revised 4-factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real-world experience

Riccardo Bomben et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Prognostic impact of the modified 4‐factor and CD49d expression. (A) Kaplan–Meier curves of modified 4‐factor comparing progression‐free survival (PFS) probabilities of 215 cases with low‐risk (low, green line), 108 cases with intermediate‐risk (int, orange line), and 78 cases with high‐risk (high, red line); (B) Kaplan–Meier curves of modified 4‐factor comparing overall survival (OS) probabilities of 215 cases with low‐risk (low, green line), 108 cases with intermediate‐risk (int, orange line), and 78 cases with high‐risk (high, red line). (C) Kaplan–Meier curves of CD49d expression (low vs. high) comparing PFS probabilities of 133 cases with CD49d low expression (CD49d‐low, green line), and 268 cases with CD49d high or bimodal expression (CD49d‐high, red line); (D) Kaplan‐Meier curves of CD49d expression (low versus high) comparing OS probabilities of 133 cases with CD49d low expression (CD49d‐low, green line), and 268 cases with CD49d high or bimodal expression (CD49d‐high, red line). (E) Kaplan–Meier curves of modified 4‐factor‐CD49d comparing PFS probabilities of 182 cases with low‐risk (low, green line), 140 cases with intermediate‐risk (int, orange line), and 79 cases with high‐risk (high, red line); (F) Kaplan–Meier curves of modified 4‐factor‐CD49d comparing OS probabilities of 182 cases with low‐risk (low, green line), 140 cases with intermediate‐risk (int, orange line), and 79 cases with high‐risk (high, red line). The number of patients in each group is reported; p values refer to log‐rank test.
See this image and copyright information in PMC

References

    1. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745‐2760. - PubMed
    1. Hallek M, Al‐Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021;96(12):1679‐1705. - PubMed
    1. Zucchetto A, Benedetti D, Tripodo C, et al. CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule‐1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Res. 2009;69(9):4001‐4009. - PubMed
    1. Tissino E, Pozzo F, Benedetti D, et al. CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression. Blood. 2020;135(15):1244‐1254. - PMC - PubMed
    1. Tissino E, Benedetti D, Herman SEM, et al. Functional and clinical relevance of VLA‐4 (CD49d/CD29) in ibrutinib‐treated chronic lymphocytic leukemia. J Exp Med. 2018;215(2):681‐697. - PMC - PubMed

LinkOut - more resources